Crossmark

Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment

Published Online: 2016-10-14

Authors

Du, F.

Yuan, P.

Zhao, Z. T.

Yang, Z.

Wang, T.

Zhao, J. D.

Luo, Y.

Ma, F.

Wang, J. Y.

Fan, Y.

Cai, R. G.

Zhang, P.

Li, Q.

Song, Y. M.

Xu, B. H.
License Information

Text and Data Mining valid from 2016-10-14

Version of Record valid from 2016-10-14
More Information

Article History

First Online: 14 October 2016

Document is current